You're implying that FSD is based entirely on GPS. You are entirely incorrect.

Rarely do I see pre-market volume. 2K so far today. Nice.

Officers come and go.

My take on FDA delay: FDA wants to see full details concerning the following sentence:

re. "the difference was in the dosages examined in Part A"
So Part A ran all the 30mg and now they're running all the 60mg? What next? All the placebos?

Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents
https://ir.coyatherapeutics.com/news/news-details/2024/Coya-Therapeutics-Expands-Pipeline-and-Intellectual-Property-Portfolio-with-Filing-of-New-U.S.-Patents-for-COYA-301-in-Combination-with-Glucagon-Like-Peptide-1-GLP-1-Receptor-Agonists/default.aspx

COYA to present AD results at CTAD24
https://ir.coyatherapeutics.com/news/news-details/2024/Coya-Therapeutics-Announces-that-Results-from-a-Double-Blind-Placebo-Controlled-Study-in-Alzheimers-Disease-will-be-presented-on-October-29-2024-at-the-Clinical-Trials-on-Alzheimers-Disease-Conference-CTAD24-in-Madrid/default.aspx

Truly good news! This establishes a pattern of new applications.

Thank You Janice! Amit has sprung from Non-Existent posting history, so I was wondering.

The original ethe is now divided into new AMEX:ethe (trust) + AMEX:eth (etf). Not whatever this NYSE shit is.

WTF? Looks like they just shaved off 10% of $ETHE to create $ETH.

Sitrick And Company is Cassava's new PR firm. What do you think about that?

Wow! Just saw. What's missing is the motive.
We are left with guessing and that's not a good place to be.
I'm out. Been out.

I haven't posted in a while. Waiting for results.

Coya 8K July 15
On June 14, 2024, Coya Therapeutics, Inc. (the “Company”) submitted to the U.S. Food and Drug Administration (the “FDA”) an Investigational New Drug Application (the “IND”) seeking to initiate a study entitled “Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 24-Week Study with Additional 24-Week Open Label Extension (OLE) to Evaluate the Safety and Efficacy of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)” (the “Study”). On July 12, 2024, the Company received an email notification from the FDA stating that additional non-clinical data is required prior to the initiation of the Study. The FDA also stated that it would provide the Company with more details about what additional information it requires within the next thirty (30) days.
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001835022/000119312524178809/d762748d8k.htm

Why would Cytodyn announce a pre-clinical study for MASH?
The FDA Has Approved a New Treatment for a Liver Disease Called MASH (Metabolic Dysfunction-Associated Steatohepatitis)

NEW YORK , June 26, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that the Food & Drug Administration (FDA) has authorized an Investigational New Drug (IND) application for Bryostatin-1 as a potential treatment for multiple sclerosis (MS).

I know my previous post was a bit mysterious but perhaps the following video will help to clarify.

Filamin-A is a scaffolding protein. Here is page 13 from the latest Cassava corp presentation.
Do you see that Destabilized Microtibule? That may be playing a role in ALZ.
The relationship was first conjectured by Roger Penrose (physicist) and Stuart Hameroff (anesthesiologist) .
Recently this conjecture has advanced to become a hypothesis

Read all about it 10am EDT
https://www.sec.gov/Archives/edgar/data/1314052/000173112224000730/e5638_def14a.htm

What going on with $HUMA? Well, I'll tell ya.
(1) New Diagnostic/Billing Codes
(2) Director Unloads 10%
(3) Yawn, Tuberville sold HUMA

Anecdotal observation of MCD. Order a shake or McFlurry. The machines are broken. And I mean broken for months.

LOL. You'll have to ask his accounting man.

The WOW signal!
Prior to initiating treatment, patients were declining at an average rate of -1.1 points per month on the ALSFRS-R rating scale- At the end of 6 months of treatment, the mean rate of change on the ALSFRS-R was +0.04 points per month.

$COYA ALS Peer-Reviewed Publication:
https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1415106/full

Dang MsPoopyHead.
You should meet MrHankey

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologic intended to enhance regulatory T cell (Treg) function, announces the acceptance of a peer-reviewed manuscript titled, “A Phase 1 Proof-of-Concept Study Evaluating Safety, Tolerability, and Biological Marker Responses with Combination Therapy of CTLA4-Ig and Interleukin-2 in Amyotrophic Lateral Sclerosis,” in the medical journal Frontiers in Neurology. A portion of the data from the manuscript was previously presented at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference and the 2024 Society of Neuroimmune Pharmacology Conference.
https://ih.advfn.com/stock-market/NASDAQ/coya-therapeutics-COYA/stock-news/93970259/coya-therapeutics-announces-acceptance-of-peer-rev

Today 2 Jun is #LouGehrigDay #EndALS

Yeah Yahoo doesn't want you clicking off-site. They lose ad revenue.

Anyone placing huge market sell orders like that is a f**king moron.

It’s T+1 time

It’s T+1 time!

re. "here is the response."
here is (A SMALL PORTION OF) the (COMPLETE) response.

May Employee Stock Option disclosures. All options granted vest over 48 months at 1/48th each month. All options have a cost basis of $22.10
10,000 James Kupiec Chief Medical Officer
10,000 Robert Cook SVP & General Counsel
25,000 Eric Schoen Chief Financial Officer
50,000 Remi Barbier President & CEO

Taysha may have the real ONE-SHOT genetic cure. It may REALLY work.
Good luck getting any health insurance plan to list this $Million dollar shot in their drug formulary.

IDK. Kick1's still in IHUB jail and his parole date has come and gone.

On May 17, 2024, Coya Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the Alzheimer’s Drug Discovery Foundation (the “ADDF”) for the issuance and sale in a private placement (the “Private Placement”) of 603,136 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”), at a purchase price of $8.29 per share for gross proceeds to the Company of $5.0 million.
ADDF >>>> https://www.alzdiscovery.org/
8K >>>>>>> https://www.sec.gov/ix?doc=/Archives/edgar/data/0001835022/000119312524142950/d820823d8k.htm

I have an idea.
Try removing those rose-colored glasses.

What a freaking dud. $SCPH

Yeah. The whole play was to halt sava's clinical trials. Obviously that play didn't work.